Nadia Waheed insider trades: Ocular Therapeutix (OCUL) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Nadia reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | OCUL | ↓ Sell | 3,510 | $7.74 | $27K | Direct | Feb 24, 2026 (4d) |
| Feb 12, 2026 | OCUL | ↓ Sell | 7,863 | $9.04 | $71K | Direct | Feb 17, 2026 (5d) |
| Jun 2, 2025 | OCUL | ↓ Sell | 13,861 | $8.05 | $112K | Direct | Jun 3, 2025 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other OCUL insiders
Open-market trades in the last 12 months
About Nadia Waheed's insider trades
Nadia Waheed is Chief Medical Officer at Ocular Therapeutix (OCUL). Since Jun 2, 2025, Nadia has reported no open-market purchases and 3 sales worth $210K on SEC Form 4. In the last 12 months: 2 sales ($98K).
Their filings also include grants and awards (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OCUL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.